Bachurski P, Chmiel G, Kalinowski P, Międlar M, Muda M, Pacek S, et al. Optimal First-Line Use of Pembrolizumab in Metastatic Driver-Negative NSCLC: Monotherapy Versus Chemo-Immunotherapy (Evidence 2022–2025). Qual Sport [Internet]. 2026 Jan. 31 [cited 2026 Feb. 1];51:68252. Available from: https://apcz.umk.pl/QS/article/view/68252